TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2340539
Drug: ORS‐90 (WHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS‐90 (WHO ORS) with sodium 90 mmol/L and glucose 111 mmol/L, osmolality 311 mosm/kg
Study: 2340539
Drug: ORS‐60 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS‐60 with sodium 60 mmol/L and glucose 90 mmol/L, osmolality 240 mosm/kg
Study: 7282615
Drug: Aspartame (34
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (34 mg/kg body weight)
Study: 7282615
Drug: Sucrose (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (1 g/kg body weight)
Study: 20473540
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field therapy (PEMF)
Study: 6143039
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (after 8 weeks without treatment)
Study: 27328752
Drug: Naltrexone/bupropion (NB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone/bupropion (NB) 32/360 mg
Study: 24251424
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement drinks served in a glass/beaker
Study: 24251424
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement drinks served via straw
Study: 20200540
Drug: Multinutrient supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multinutrient supplement providing increased protein and energy (P/E)
Study: 17638495
Drug: Positive display
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Positive display rules (e.g., be enthusiastic and hide frustration)
Study: 15947510
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to related and other cues followed by well-being therapy (WBT)
Study: 7597439
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus carboplatin (doses escalated from 300 to 450 mg/m2 for carboplatin and 125 to 175 mg/m2 for paclitaxel)
Study: 2113764
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (15 mg)
Study: 30584782
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (CT; multimodal therapy plus aerobic training)
Study: 27490162
Drug: Tiotropium Respimat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium Respimat 5 µg
Study: 27490162
Drug: Tiotropium Respimat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium Respimat 2.5 µg
Study: 27490162
Drug: HandiHaler 18
Normalized name: Spiriva HandiHaler 18 MCG Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: HandiHaler 18 µg
Study: 19197174
Drug: Couple-based interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couple-based interventions that educate both partners about the woman's diagnosis and treatments, promote mutual coping and support, and include sexual therapy techniques.
Study: 19197174
Drug: Interventions including
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interventions including sexual therapy techniques
Study: 17084676
Drug: Vagus nerve
Normalized name: SUS SCROFA VAGUS NERVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vagus nerve stimulation (VNS) therapy
Study: 17203016
Drug: VNS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VNS therapy
Study: 15206991
Drug: Terbogrel 150
Normalized name: Terbogrel
DrugBank: Terbogrel (DB12204)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbogrel 150 mg
Study: 15206991
Drug: Terbogrel 50
Normalized name: Terbogrel
DrugBank: Terbogrel (DB12204)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbogrel 50 mg, 100 mg, 150 mg
Study: 15206991
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 330 mg once-a-day
Study: 11143737
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 550 mg or ibuprofen 400 mg
Study: 9360028
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day ASA at Time 2 (7h to 9h after awakening)
Study: 9360028
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day ASA at Time 3 (within 2h of bedtime)
Study: 9360028
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day ASA at Time 2 (7h to 9h after awakening)
Study: 9360028
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day ASA for hypertensive patients at Time 2 (7h to 9h after awakening)
Study: 9360028
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day ASA for hypertensive patients at Time 3 (within 2h of bedtime)
Study: 3009050
Drug: Abrupt withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrupt withdrawal of beta-blockers (group 1)
Study: 3009050
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (group 1)
Study: 3009050
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of beta-blockade therapy (group 4)
Study: 25028177
Drug: Antiarrhythmic Drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic Drug Therapy (ADT)
Study: 11855793
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg daily)
Study: 9180836
Drug: Ifosfamide 15
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide 15 g/m2/cycle
Study: 9180836
Drug: Ifosfamide 3
Normalized name: ifosfamide 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 3 g/m2 during 5 days
Study: 1587761
Drug: Twice-a-day radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-a-day radiation therapy (hyperfractionation) delivering 120 cGy per fraction, two fractions a day for a total of 6000 cGy in 50 fractions over 5 weeks
Study: 3929934
Drug: Duodenal capsule
Normalized name: Sus scrofa duodenum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duodenal capsule biopsy
Study: 3929934
Drug: Jejunal capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jejunal capsule biopsy
Study: 31667062
Drug: Saracatinib 125
Normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saracatinib 125 mg/day for 28 days
Study: 27755159
Drug: Peony-Glycyrrhiza Decoction
Normalized name: GLYCYRRHIZA
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peony-Glycyrrhiza Decoction (PGD) 45 g/d for 16 weeks
Study: 20542963
Drug: Modified-release (MR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release (MR) prednisone (2-10 mg/day)
Study: 17054466
Drug: Raloxifene (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (180 mg/day) + Oestradiol (100 microg/24 h for last 10 days)
Study: 17054466
Drug: Clomiphene (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene (150 mg/day) + Oestradiol (100 microg/24 h for last 10 days)
Study: 17054466
Drug: Oestradiol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol (100 microg/24 h for 30 days) + Raloxifene (180 mg/day for last 10 days)
Study: 17054466
Drug: Oestradiol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol (100 microg/24 h for 30 days) + Clomiphene (150 mg/day for last 10 days)
Study: 11937566
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg BIRB 796 BS
Study: 11937566
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg BIRB 796 BS
Study: 7933324
Drug: Diphtheria and
Normalized name: Diphtheria and tetanus vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria and tetanus toxoid vaccine (DT) primed infants given PRP-T
Study: 7933324
Drug: Diphtheria and
Normalized name: Diphtheria and tetanus vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria and tetanus toxoid vaccine (DT) primed infants given HbOC
Study: 29520889
Drug: Artichoke leaf
Normalized name: artichoke leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artichoke leaf extract (ALE) 600 mg daily
Study: 28443702
Drug: Turmeric supplementation
Normalized name: Turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric supplementation (6 capsules daily for 12 weeks, each containing 500 mg turmeric powder)
Study: 28443702
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 capsules daily for 12 weeks)
Study: 9764991
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day for 2 weeks (Group 1)
Study: 9764991
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg twice a week for 2 weeks (Group 2)
Study: 9764991
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg once a week for 2 weeks (Group 3)
Study: 9764991
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg once a week for 12 weeks (Group 4)
Study: 8550361
Drug: Subcutaneous sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous sumatriptan 6 mg (second injection)
Study: 8550361
Drug: Subcutaneous sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous sumatriptan 6 mg (rescue medication)
Study: 719892
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg vitamin E daily for two weeks
Study: 31833004
Drug: Pseudo-laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudo-laser treatment
Study: 21812357
Drug: Magnesium carbonate
Normalized name: Magnesium Carbonate
DrugBank: Magnesium carbonate (DB09481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium carbonate 3 x 1 g
Study: 21812357
Drug: Sevelamer hydrochloride
Normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer hydrochloride 0.8 g‐‐3 x 2 tabl (3 x 1.6 g)
Study: 21812357
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate 3 x 2 g
Study: 10965439
Drug: Trimovax vaccine
Normalized name: rabies virus vaccine wistar strain PM-1503-3M (human), inactivated Injection [Imovax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimovax vaccine
Study: 9244021
Drug: First arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: First arterial sample (discard volume 4.5 ml)
Study: 9244021
Drug: Second arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second arterial sample (discard volume 16 ml)
Study: 22575796
Drug: Traditional center-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional center-based exercise therapy approach (TRAD)
Study: 25894719
Drug: Manual injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual injection
Study: 13678478
Drug: Clarithromycin extended-release
Normalized name: Clarithromycin Extended-Release Tablets
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin extended-release (ER) 500 mg once daily for 5 days
Study: 13678478
Drug: Clarithromycin immediate-release
Normalized name: clarithromycin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin immediate-release (IR) 250 mg twice daily for 5 days
Study: 1735395
Drug: Tramadol 15
Normalized name: traMADol 150 mg/24 hours oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 15 mg h‐1 infusion (Group I)
Study: 6336600
Drug: Spironolactone, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone, 400 mg/d
Study: 6336600
Drug: Chlorthalidone, 100
Normalized name: Chlorthalidone, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone, 100 mg/d
Study: 30723231
Drug: Placebos provided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos provided with a psychological treatment rationale
Study: 27843307
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (CLA) supplementation, 3.2 g daily for 6 weeks
Study: 24621319
Drug: Zonisamide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide (1 mg/kg/day up-titrated to 8 mg/kg/day, maximum 500 mg/day)
Study: 17501980
Drug: Nobel Direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nobel Direct and Nobel Perfect one-piece implants (OPIs)
Study: 17501980
Drug: Two-piece implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-piece implants (TPIs)
Study: 29581202
Drug: Non-interventional methods
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-interventional methods for assessing COPD treatment effectiveness
Study: 26562679
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of motivational enhancement and cognitive behavioral therapy
Study: 26562679
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment plus additional 'check-up' sessions
Study: 18178097
Drug: Novel agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel agents (thalidomide, lenalidomide, bortezomib, dexamethasone)
Study: 8790203
Drug: Rhenium-186-etidronate (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhenium-186-etidronate (doses ranging from 1295 MBq to 3515 MBq)
Study: 6734920
Drug: Dicyclomine (Merbentyl)
Normalized name: dicyclomine hydrochloride Oral Tablet [Merbentyl]
DrugBank: Dicyclomine (DB00804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dicyclomine (Merbentyl) + Antacid
Study: 27252426
Drug: ETN reduced-dose
Normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETN reduced-dose group
Study: 21279478
Drug: Mesalamine 800
Normalized name: mesalamine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine 800 mg b.i.d for 10 days every month
Study: 21279478
Drug: No 5-ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: No 5-ASA medications
Study: 20709109
Drug: Hydroxyethyl cellulose
Normalized name: Hydroxyethyl Cellulose
DrugBank: Hydroxyethyl cellulose (DB11602)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl cellulose (HEC) gel
Study: 20709109
Drug: Methylcellulose (MC)
Normalized name: Methylcellulose
DrugBank: Methylcellulose (DB11228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcellulose (MC) gel
Study: 20709109
Drug: Thin gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thin gel layers in Transwell system
Study: 18004139
Drug: levodopa (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodopa (100 mg)
Study: 20398447
Drug: Collagen injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen injection
Study: 11203756
Drug: Capsaicin injection
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin injection after tooth grinding (exercise session)
Study: 11203756
Drug: Capsaicin injection
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin injection without tooth grinding (non-exercise session)
Study: 8866629
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 mg) administered in the morning
Study: 8866629
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 mg) administered in the evening
Study: 8866629
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 mg) administered in the morning or evening
Study: 6143185
Drug: Gentamicin and
Normalized name: Gentamicin and prednisolone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin and clindamycin (G/C group)
Study: 26666457
Drug: Sensorimotor training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensorimotor training (SMT) with 15 minutes added to standard physiotherapy (PT) treatment
Study: 26666457
Drug: Standard physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physiotherapy (PT) treatment with 15 minutes of sub-effective low-intensity endurance training
Study: 23544761
Drug: Adherent metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherent metformin participants
Study: 17578859
Drug: Intact parathyroid
Normalized name: Intact parathyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact parathyroid hormone (iPTH) levels measured every 3 months and at relapse
Study: 17578859
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficiency defined as S-25(OH)D < or = 37 nmol/l
Study: 17578859
Drug: Calcium, phosphate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium, phosphate, magnesium, chloride, alkaline phosphatase, albumin, and thyroid stimulating hormone levels measured
Study: 10706012
Drug: German patients
Normalized name: German cockroach allergenic extract
DrugBank: Blatella germanica (DB10418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: German patients (G-Pat)
Study: 9366820
Drug: Oral terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbinafine 250 mg/day for 12 or 24 weeks
Study: 1383825
Drug: Buprenorphine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (8 mg SL daily)
Study: 1383825
Drug: Buprenorphine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (8 mg SL every other day)
Study: 30875527
Drug: ADSTEP (Assistive
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADSTEP (Assistive Device Selection, Training and Education Program) - a multicomponent program of walking aid selection, fitting and six weekly progressive task‐oriented walking aid training sessions
Study: 27146373
Drug: Daily training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily training for 12 weeks in phoneme/grapheme mapping, reading comprehension, and reading speed (Intervention group, n=47)
Study: 24498399
Drug: LMWF-5A (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWF-5A (4 mL or 10 mL)
Study: 23300745
Drug: Azacitidine 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azacitidine 37.5 mg/sqm
Study: 23300745
Drug: Azacitidine 75
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 75 mg/sqm
Study: 23300745
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (7+3 cytarabine plus daunorubicin and intermediate-dose cytarabine)
Study: 20591173
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV ibuprofen 100 mg
Study: 20591173
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV ibuprofen 200 mg
Study: 11940545
Drug: Beta-blocker nebivolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker nebivolol 5 mg daily
Study: 10633487
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose haloperidol
Study: 8746104
Drug: Cefatrizine at
Normalized name: cefatrizine
DrugBank: Cefatrizine (DB13266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefatrizine at a dose of 1 g/day for 10 days
Study: 8746104
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil at a dose of 400 mg/day for 10 days
Study: 2693918
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (50 mg i.m. every 3 or 4 weeks)
Study: 3124456
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate therapy
Study: 322696
Drug: Intravenous BCG
Normalized name: Tice BCG Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous BCG treatment
Study: 322696
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy only (DNR/ARAC)
Study: 30802689
Drug: AL 441
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL 441 mg
Study: 30802689
Drug: AL 882
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL 882 mg
Study: 16422960
Drug: Vardenafil 10
Normalized name: vardenafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 10 mg or 20 mg
Study: 17713974
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg (oral administration)
Study: 15921803
Drug: Carvedilol (non-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (non-selective beta-blocker)
Study: 11684630
Drug: Metoprolol (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (selective beta-blocker)
Study: 8599282
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 300 mg administered in a 120 min iv infusion
Study: 2698515
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg Cinoxacin b.i.d. for 5 days
Study: 30967597
Drug: CYP19A1 low
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CYP19A1 low estrogen alleles rs10046 G and rs4646 A
Study: 26531075
Drug: Minimal caries
Normalized name: Tilletia caries
DrugBank: Tilletia caries (DB10705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal caries removal with both resin‐modified glass ionomer base material and luting cement (MCRB/L)
Study: 23627832
Drug: DBX (thermogenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBX (thermogenic dietary supplement containing 340 mg of total caffeine plus green tea extract, yerba mate extract, carnitine tartrate)
Study: 21628014
Drug: MiroCam capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: MiroCam capsule
Study: 16923310
Drug: Glutamine and
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine and antioxidant therapy